Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China approves Innovent sNDA for hepatocellular carcinoma treatment
Discovered and developed by Lilly, Cyramza has been approved for the treatment of HCC patients with an alpha fetoprotein of ≥400 ng/mL and who have received treatment with
Discovered and developed by Lilly, Cyramza has been approved for the treatment of HCC patients with an alpha fetoprotein of ≥400 ng/mL and who have received treatment with
Oxlumo, which is administered through subcutaneous injection, has now been indicated to treat PH1 to reduce the levels of urinary oxalate (UOx) and plasma oxalate (POx) in paediatric
The decision to not submit the EUA application was made after receiving feedback from the FDA. Last month, the company submitted a request to FDA for a pre-EUA
The partnership will particularly focus on identifying composite biomarkers, which integrate several biological entities into a single readout. This identification will help guide therapeutic decision making. Gastroesophageal cancer
The company was created after the acquisition of Alexion Pharmaceuticals by AstraZeneca last year. The aim of the acquisition is to expedite the expansion of Alexion into genomic
The new combined formulation will be delivered using a breath-actuated nebuliser. Currently, AeroRx is said to be engaged in the development of the first nebulised LABA/LAMA combination solution
The collaboration will use the companies’ respective strengths to support the development of ASO-based precision medicine therapies and for creating compelling value opportunities for Vanda and OliPass. It
This approval makes Dupixent the first and only medicine available in the US for the treatment of prurigo nodularis, a chronic and debilitating skin disease. A fully human
As part of the collaboration deal, the companies will use ArsenalBio’s T cells screening and engineering technology for identifying the critical success circuits in T cell-based therapies. Genentech,
Under the deal, both entities will focus on discovering and developing new therapeutics based on small interfering RNA (siRNA) technology. The partnership will identify new therapeutic targets, which are